+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vancomycin Market by Dosage Form, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast to 2030- Product Image
Vancomycin Market by Dosage Form, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Vancomycin Market by Dosage Form, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889004
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

As demand for advanced antibacterial therapies continues to intensify, the vancomycin market maintains strategic importance for healthcare stakeholders worldwide. Senior decision-makers face a fast-evolving landscape shaped by shifting resistance patterns, supply chain challenges, and regulatory mandates.

Market Snapshot: Vancomycin Market Size and Growth Outlook

The vancomycin market achieved significant growth, advancing from USD 741.53 million in 2024 to USD 779.23 million in 2025. Future expansion is anticipated at a compound annual growth rate (CAGR) of 4.99%, with projections estimating a market value of USD 993.37 million by 2030. This trajectory reflects robust global demand for vancomycin as both inpatient and outpatient sectors adapt to emerging prescribing standards and the ongoing need for reliable antibacterial agents.

Scope & Segmentation

This comprehensive report assesses vancomycin’s market across all critical dimensions, enabling precise benchmarking and strategy development:

  • Dosage Forms: Lyophilized powder for injection, oral formulation, and solution for injection.
  • Routes of Administration: Intravenous and oral.
  • Indications: Clostridioides difficile infections, methicillin-resistant Staphylococcus aureus treatment, surgical prophylaxis.
  • End Users: Ambulatory surgical centers (multi-specialty and single-specialty), clinics (outpatient and specialty), hospitals (community and tertiary care).
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • Regions Covered: Americas (with detailed country-level segmentation), Europe, Middle East & Africa, and Asia-Pacific.
  • Technology & Service Models: Includes digital health tools, real-time tracking platforms, telemedicine, home infusion, API sourcing strategies, and service-based innovations.
  • Company Coverage: Profiles industry players across multinational, mid-tier, and specialty biotech segments, capturing all market leader and challenger strategies.

Key Takeaways: Strategic Insights for Decision-Makers

  • Generic competition continues to intensify, influencing procurement strategies and placing downward pressure on pricing across both hospital and outpatient settings.
  • API availability and quality are driving alliances and dual-sourcing approaches, as supply chain resilience gains focus amid shifting trade dynamics.
  • Technological innovation—in digital health, data analytics, and patient-centric offerings—differentiates market leaders and aligns with evolving care delivery models.
  • Formulation trends indicate sustained dominance of intravenous presentations for acute care, with oral vancomycin gaining traction in home infusion and telehealth environments.
  • Ambulatory and specialty clinics increasingly shape demand through their adoption of streamlined protocols, just-in-time inventory systems, and digital procurement tools.
  • Regional disparities require nuanced strategies, with regulatory, funding, and market access conditions impacting uptake and distribution patterns worldwide.

Tariff Impact: Navigating Global Supply Chain Pressures

Recent and proposed tariffs on active pharmaceutical ingredients sourced from major Asian suppliers are expected to present new cost challenges for vancomycin producers. Organizations are responding by reconfiguring procurement partnerships, exploring nearshoring, and boosting local API manufacturing capacity to alleviate potential disruptions and mitigate long-term budgetary pressures on hospitals and clinics.

Methodology & Data Sources

This analysis synthesizes primary interviews with executives, pharmacists, and supply chain experts, combining these with robust secondary data from regulatory filings, peer-reviewed literature, and public health platforms. All findings are rigorously validated, ensuring data consistency through reconciliation protocols and expert peer review.

Why This Report Matters

  • Gives executives a clear view of market-defining trends, procurement risks, and regulatory shifts essential for confident planning and investment.
  • Enables targeted strategy development across dosage forms, care settings, and regional markets to support operational and commercial objectives.
  • Delivers actionable intelligence to inform formulation optimization, supply chain diversification, and partnership opportunities that shape competitive positioning.

Conclusion

With shifting clinical requirements and supply chain dynamics, operational flexibility and evidence-driven strategies are vital for success in the vancomycin market. This research provides a structured foundation to support resilient decision-making and robust growth initiatives.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vancomycin Market, by Dosage Form
8.1. Introduction
8.2. Lyophilized Powder For Injection
8.3. Oral Formulation
8.4. Solution For Injection
9. Vancomycin Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Vancomycin Market, by Indication
10.1. Introduction
10.2. Clostridioides Difficile Infections
10.3. Methicillin Resistant Staphylococcus Aureus Treatment
10.4. Surgical Prophylaxis
11. Vancomycin Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.2.1. Multi Specialty Centers
11.2.2. Single Specialty Centers
11.3. Clinics
11.3.1. Outpatient Clinics
11.3.2. Specialty Clinics
11.4. Hospitals
11.4.1. Community Hospitals
11.4.2. Tertiary Care Hospitals
12. Vancomycin Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Vancomycin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vancomycin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vancomycin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Novartis AG
16.3.4. Viatris Inc.
16.3.5. Fresenius Kabi AG
16.3.6. Hikma Pharmaceuticals PLC
16.3.7. Dr. Reddy’s Laboratories Ltd.
16.3.8. Aurobindo Pharma Limited
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.10. Glenmark Pharmaceuticals Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VANCOMYCIN MARKET MULTI-CURRENCY
FIGURE 2. VANCOMYCIN MARKET MULTI-LANGUAGE
FIGURE 3. VANCOMYCIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VANCOMYCIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 53. CANADA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. CANADA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 57. CANADA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 58. CANADA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 59. CANADA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MEXICO VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 61. MEXICO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. GERMANY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 102. GERMANY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. GERMANY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. GERMANY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. GERMANY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. FRANCE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 110. FRANCE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. FRANCE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. FRANCE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. FRANCE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ITALY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. ITALY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ITALY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. ITALY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ITALY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 130. ITALY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 131. ITALY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 132. ITALY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SPAIN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. SPAIN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. SPAIN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. SPAIN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. SPAIN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. DENMARK VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 166. DENMARK VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. DENMARK VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. DENMARK VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. DENMARK VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. QATAR VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. QATAR VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. QATAR VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. QATAR VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. QATAR VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 186. QATAR VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 187. QATAR VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. QATAR VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. FINLAND VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 190. FINLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. FINLAND VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. FINLAND VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. FINLAND VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. EGYPT VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. EGYPT VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. EGYPT VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. EGYPT VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. EGYPT VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. TURKEY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 222. TURKEY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. TURKEY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. NORWAY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 238. NORWAY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. NORWAY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. NORWAY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. NORWAY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. POLAND VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. POLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. POLAND VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. POLAND VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. POLAND VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 250. POLAND VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 251. POLAND VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. POLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. CHINA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 271. CHINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. CHINA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. CHINA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. CHINA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 275. CHINA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 276. CHINA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. CHINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. INDIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 279. INDIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. INDIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. INDIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. INDIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 283. INDIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 284. INDIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 285. INDIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. JAPAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 287. JAPAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. JAPAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. JAPAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. JAPAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. THAILAND VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 319. THAILAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. THAILAND VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 321. THAILAND VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. THAILAND VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 323. THAILAND VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 324. THAILAND VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 350. VIETNAM VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 351. VIETNAM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 352. VIETNAM VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 353. VIETNAM VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. VIETNAM VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 355. VIETNAM VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 357. VIETNAM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 358. TAIWAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 359. TAIWAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 360. TAIWAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 361. TAIWAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 362. TAIWAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 363. TAIWAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 364. TAIWAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 365. TAIWAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 366. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2024
TABLE 367. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Vancomycin market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Viatris Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 779.23 Million
Forecasted Market Value ( USD ) by 2030 $ 993.37 Million
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vancomycin - Global Strategic Business Report - Product Image

Vancomycin - Global Strategic Business Report

  • Report
  • 78 Pages
  • Global
From
Vancomycin Market Report 2025 - Product Image

Vancomycin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2025 - Product Image

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Vancomycin Resistant Enterococcal Infections - Pipeline Insight, 2025 - Product Image

Vancomycin Resistant Enterococcal Infections - Pipeline Insight, 2025

  • Drug Pipelines
  • 40 Pages
  • Global
From
2024-2028 Global Vancomycin-Resistant Enterococcus (VRE) Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation - Product Image

2024-2028 Global Vancomycin-Resistant Enterococcus (VRE) Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation

  • Report
  • Global
From

About the Vancomycin Market

Vancomycin is an antibiotic used to treat a wide range of bacterial infections. It is a glycopeptide antibiotic, derived from the bacterium Amycolatopsis orientalis, and is used to treat infections caused by Gram-positive bacteria. Vancomycin is often used as a last-resort antibiotic, when other antibiotics have failed to treat an infection. It is also used to treat infections caused by Clostridium difficile, a bacterium that can cause severe diarrhea. Vancomycin is available in both oral and intravenous forms, and is used to treat a variety of infections, including skin and soft tissue infections, bone and joint infections, and endocarditis. It is also used to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is a widely used antibiotic, and is available from a number of pharmaceutical companies, including Pfizer, Merck, and AstraZeneca. It is also available in generic form from a number of generic drug manufacturers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.